Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Go back to Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 161.44 -0.18 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $161.62 | 52 Week High | $58.46 | |||
| Open | $161.62 | 52 Week Low | $31.25 | |||
| Day High | $163.53 | P/E | N/A | |||
| Day Low | $160.42 | EPS | $-0.69 | |||
| Volume | 1,037,234 | |||||
| (NASDAQ: SLNO) | Delayed: 53.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.01 | 52 Week High | $ | |||
| Open | $53.01 | 52 Week Low | $ | |||
| Day High | $53.01 | P/E | N/A | |||
| Day Low | $53.01 | EPS | $ | |||
| Volume | 158,534 | |||||
